Not logged in.png)
Share.png)
SaveShare Save Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6-17 Years: An Immunobridging Trial
Han, Xu; Wei, Mingwei; Zheng, Xiuyu; Wan, Peng; Tang, Jie; Zhang, Lu; Zhang, Shupeng; Zhou, Hanchi; Lu, Jiayu; Zhou, Li; Zhu, Yawen; Li, Jingxin; Zhu, Fengcai Share Save Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapyWan, Peng; Zhong, Liang; Yu, Lihua; Shen, Chenlan; Shao, Xin; Chen, Shuyu; Zhou, Ziwei; Wang, Meng; Zhang, Hongyan; Liu, Beizhong Share Save The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in ChinaJiang, Hudachuan; Jin, Pengfei; Guo, Xiling; Zhu, Jiahong; Wang, Xue; Wan, Peng; Wan, Jingxuan; Liu, Jingxian; Li, Jingxin; Zhu, Fengcai Share Save Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort studyXu, Nani; Xu, Yu; Dai, Rongrong; Zheng, Lin; Qin, Pan; Wan, Peng; Yang, Yejing; Jiang, Jianmin; Zhang, Hangjie; Hu, Xiaowei; Lv, Huakun Share Save Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trialWu, Jun -Dong; Li, Jing-Xin; Liu, Jian; Wang, Hao-Meng; Zhou, Guang-Hui; Li, Jin; Wu, Dou; Chen, Xiang; Feng, Yan; Qi, Xiao-Yuan; Wang, Xue; Gou, Jin-Bo; Ma, Tie-Liang; Yang, Xiao-Yun; Xu, Li-Feng; Wan, Peng; Zhu, Tao; Wang, Zhong-Fang; Zhu, Feng-Cai Share Save Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialJin, Peng-Fei; Guo, Xi-Ling; Gou, Jin-Bo; Hou, Li-Hua; Song, Zhi-Zhou; Zhu, Tao; Pan, Hong-Xing; Zhu, Jia-Hong; Shi, Feng-Juan; Du, Pan; Huang, Hai-Tao; Liu, Jing-Xian; Zheng, Hui; Wang, Xue; Chen, Yin; Wan, Peng; Wu, Shi-Po; Wang, Xue-Wen; Xu, Xiao-Yu; Yan, Fang-Rong; Li, Jing-Xin; Chen, Wei; Zhu, Feng-Cai Share Save Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trialWu, Yan-Fei; Wei, Ming-Wei; Wang, Rui-Jie; Guo, Xi-Ling; Pan, Hong-Xing; Gao, Ya-Chun; Li, Xiao-Long; Wang, Xue; Ma, Xiao-Min; Wan, Peng; Zhou, Li; Zhu, Ya-Wen; Li, Jing-Xin; Zhu, Feng-Cai Share Save Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical TrialsXia, Xin; Tan, Zhong-Ming; Wan, Peng; Zheng, Hao; Tang, Rong; Chen, Xiao-Qin; Guo, Xi-Ling; Zhu, Tao; Feng, Jia-Lu; Zhong, Jin; Li, Xiao-Long; Zhang, Zhen-Yu; Zhu, Feng-Cai; Li, Jing-Xin Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
